Guest guest Posted November 19, 2011 Report Share Posted November 19, 2011 I wonder if the side effects would be worse. Penny > > > Boehringer's Hepatitis C Drug Candidate May Compete with the Newest Treatments > Treatment Time Gets Shorter > > November 14, 2011 > Printer-friendly version > Similar to the new Hepatitis C drug Telaprevir, Boehringer's protease inhibitor could reduce total treatment time to three months and improve the chances of success in the hardest-to-treat Hep C cases. > Boehringer hails hepatitis C candidate > Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients' treatment time and help in hard-to-treat cases. > The treatment of hepatitis C has moved forward recently, with Janssen's Incivo (telaprevir) and Merck and Roche's Victrelis (boceprevir) both recently launched in Europe. > Boehringer says its drug BI 201335 could cut the time a patient needed to take the drug to 12 weeks, matching the performance of Incivo. > The phase IIb studies SILEN-C1 and SILEN-C3 combined the protease inhibitor with standard of care pegylated interferon (PegIFN) and ribavirin (RBV) - which is only successful in about half of all cases - in previously untreated genotype 1 (GT1) HCV patients. > Continue reading this entire article: > http://www.inpharm.com/news/169774/boehringer-hails-hepatitis-c-candidate > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 19, 2011 Report Share Posted November 19, 2011 I think the main side affect is diarrhea, and that can be controlled with Lomotil. Love Janet "There are souls in this world that have the gift of finding joy everywhere and of leaving it behind them when they go" Frederick Faber To: Hepatitis_C_Central Sent: Saturday, November 19, 2011 2:49 PMSubject: Re: Fw: New Drug I wonder if the side effects would be worse.Penny>> > Boehringer's Hepatitis C Drug Candidate May Compete with the Newest Treatments> Treatment Time Gets Shorter> > November 14, 2011> Printer-friendly version > Similar to the new Hepatitis C drug Telaprevir, Boehringer's protease inhibitor could reduce total treatment time to three months and improve the chances of success in the hardest-to-treat Hep C cases.> Boehringer hails hepatitis C candidate> Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients' treatment time and help in hard-to-treat cases.> The treatment of hepatitis C has moved forward recently, with Janssen's Incivo (telaprevir) and Merck and Roche's Victrelis (boceprevir) both recently launched in Europe.> Boehringer says its drug BI 201335 could cut the time a patient needed to take the drug to 12 weeks, matching the performance of Incivo.> The phase IIb studies SILEN-C1 and SILEN-C3 combined the protease inhibitor with standard of care pegylated interferon (PegIFN) and ribavirin (RBV) - which is only successful in about half of all cases - in previously untreated genotype 1 (GT1) HCV patients. > Continue reading this entire article:> http://www.inpharm.com/news/169774/boehringer-hails-hepatitis-c-candidate> Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 20, 2011 Report Share Posted November 20, 2011 I am in my 3rd week of interferon treatment. Next week I start that drug. Its for 12 weeks. I will keep you all posted on how its going. Last week my wbc dropped to 1.6 so they gave me a shot of nupr. I feel okay just a little ichy which I did not have last time. I have been working full days so far. Lets see how it goes. I have a good attitude. Subject: Re: Fw: New DrugTo: Hepatitis_C_Central Date: Saturday, November 19, 2011, 12:49 PM I wonder if the side effects would be worse.Penny>> > Boehringer's Hepatitis C Drug Candidate May Compete with the Newest Treatments> Treatment Time Gets Shorter> > November 14, 2011> Printer-friendly version > Similar to the new Hepatitis C drug Telaprevir, Boehringer's protease inhibitor could reduce total treatment time to three months and improve the chances of success in the hardest-to-treat Hep C cases.> Boehringer hails hepatitis C candidate> Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients' treatment time and help in hard-to-treat cases.> The treatment of hepatitis C has moved forward recently, with Janssen's Incivo (telaprevir) and Merck and Roche's Victrelis (boceprevir) both recently launched in Europe.> Boehringer says its drug BI 201335 could cut the time a patient needed to take the drug to 12 weeks, matching the performance of Incivo.> The phase IIb studies SILEN-C1 and SILEN-C3 combined the protease inhibitor with standard of care pegylated interferon (PegIFN) and ribavirin (RBV) - which is only successful in about half of all cases - in previously untreated genotype 1 (GT1) HCV patients. > Continue reading this entire article:> http://www.inpharm.com/news/169774/boehringer-hails-hepatitis-c-candidate> Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 20, 2011 Report Share Posted November 20, 2011 HI ,Just to let you and the group know:My grandmother in law discovered she had hep C in July. HCV RNA (Taqman) was in the order 5.5 millionNow, in November this has been reduced to around 500,000.Ribavirin, 8 x 3 activated drop of MMS and one hour after the last dose 10 grams of vit C. Supplemented also with 20,000 IU of vit D3 to bring it up from 10 ng/ml to 60 ng/ml.No side effects until now.Additional benefit of MMS: Her bacterial count in the urine went from 280 to 47 and White and Red blood cells in urine were 50 % of the value when started this regime.Best regards,Jan PHo Chi Minh To: Hepatitis_C_Central Sent: Monday, November 21, 2011 12:45 AM Subject: Re: Re: Fw: New Drug I am in my 3rd week of interferon treatment. Next week I start that drug. Its for 12 weeks. I will keep you all posted on how its going. Last week my wbc dropped to 1.6 so they gave me a shot of nupr. I feel okay just a little ichy which I did not have last time. I have been working full days so far. Lets see how it goes. I have a good attitude. Subject: Re: Fw: New DrugTo: Hepatitis_C_Central Date: Saturday, November 19, 2011, 12:49 PM I wonder if the side effects would be worse.Penny>> > Boehringer's Hepatitis C Drug Candidate May Compete with the Newest Treatments> Treatment Time Gets Shorter> > November 14, 2011> Printer-friendly version > Similar to the new Hepatitis C drug Telaprevir, Boehringer's protease inhibitor could reduce total treatment time to three months and improve the chances of success in the hardest-to-treat Hep C cases.> Boehringer hails hepatitis C candidate> Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients' treatment time and help in hard-to-treat cases.> The treatment of hepatitis C has moved forward recently, with Janssen's Incivo (telaprevir) and Merck and Roche's Victrelis (boceprevir) both recently launched in Europe.> Boehringer says its drug BI 201335 could cut the time a patient needed to take the drug to 12 weeks, matching the performance of Incivo.> The phase IIb studies SILEN-C1 and SILEN-C3 combined the protease inhibitor with standard of care pegylated interferon (PegIFN) and ribavirin (RBV) - which is only successful in about half of all cases - in previously untreated genotype 1 (GT1) HCV patients. > Continue reading this entire article:> http://www.inpharm.com/news/169774/boehringer-hails-hepatitis-c-candidate> Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 20, 2011 Report Share Posted November 20, 2011 To: "Hepatitis_C_Central " <Hepatitis_C_Central > Sent: Monday, November 21, 2011 7:29 AM Subject: Re: Re: Fw: New Drug HI ,Just to let you and the group know:My grandmother in law discovered she had hep C in July. HCV RNA (Taqman) was in the order 5.5 millionNow, in November this has been reduced to around 500,000.Ribavirin, 8 x 3 activated drop of MMS and one hour after the last dose 10 grams of vit C. Supplemented also with 20,000 IU of vit D3 to bring it up from 10 ng/ml to 60 ng/ml.No side effects until now.Additional benefit of MMS: Her bacterial count in the urine went from 280 to 47 and White and Red blood cells in urine were 50 % of the value when started this regime.Best regards,Jan PHo Chi Minh To: Hepatitis_C_Central Sent: Monday, November 21, 2011 12:45 AM Subject: Re: Re: Fw: New Drug I am in my 3rd week of interferon treatment. Next week I start that drug. Its for 12 weeks. I will keep you all posted on how its going. Last week my wbc dropped to 1.6 so they gave me a shot of nupr. I feel okay just a little ichy which I did not have last time. I have been working full days so far. Lets see how it goes. I have a good attitude. Subject: Re: Fw: New DrugTo: Hepatitis_C_Central Date: Saturday, November 19, 2011, 12:49 PM I wonder if the side effects would be worse.Penny>> > Boehringer's Hepatitis C Drug Candidate May Compete with the Newest Treatments> Treatment Time Gets Shorter> > November 14, 2011> Printer-friendly version > Similar to the new Hepatitis C drug Telaprevir, Boehringer's protease inhibitor could reduce total treatment time to three months and improve the chances of success in the hardest-to-treat Hep C cases.> Boehringer hails hepatitis C candidate> Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients' treatment time and help in hard-to-treat cases.> The treatment of hepatitis C has moved forward recently, with Janssen's Incivo (telaprevir) and Merck and Roche's Victrelis (boceprevir) both recently launched in Europe.> Boehringer says its drug BI 201335 could cut the time a patient needed to take the drug to 12 weeks, matching the performance of Incivo.> The phase IIb studies SILEN-C1 and SILEN-C3 combined the protease inhibitor with standard of care pegylated interferon (PegIFN) and ribavirin (RBV) - which is only successful in about half of all cases - in previously untreated genotype 1 (GT1) HCV patients. > Continue reading this entire article:> http://www.inpharm.com/news/169774/boehringer-hails-hepatitis-c-candidate> Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 21, 2011 Report Share Posted November 21, 2011 Hi , I am going to start treatment in January, but they are putting me on the Vertex drug. I believe that starts right away and in 4 weeks if I am not clear, I am done and off all treatment. If I do clear, they told me to expect to be on treatment the rest of the year. I hope all goes well for you and treatment is not too hard on you! Steph To: Hepatitis_C_Central Sent: Sunday, November 20, 2011 9:45 AMSubject: Re: Re: Fw: New Drug I am in my 3rd week of interferon treatment. Next week I start that drug. Its for 12 weeks. I will keep you all posted on how its going. Last week my wbc dropped to 1.6 so they gave me a shot of nupr. I feel okay just a little ichy which I did not have last time. I have been working full days so far. Lets see how it goes. I have a good attitude. Subject: Re: Fw: New DrugTo: Hepatitis_C_Central Date: Saturday, November 19, 2011, 12:49 PM I wonder if the side effects would be worse.Penny>> > Boehringer's Hepatitis C Drug Candidate May Compete with the Newest Treatments> Treatment Time Gets Shorter> > November 14, 2011> Printer-friendly version > Similar to the new Hepatitis C drug Telaprevir, Boehringer's protease inhibitor could reduce total treatment time to three months and improve the chances of success in the hardest-to-treat Hep C cases.> Boehringer hails hepatitis C candidate> Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients' treatment time and help in hard-to-treat cases.> The treatment of hepatitis C has moved forward recently, with Janssen's Incivo (telaprevir) and Merck and Roche's Victrelis (boceprevir) both recently launched in Europe.> Boehringer says its drug BI 201335 could cut the time a patient needed to take the drug to 12 weeks, matching the performance of Incivo.> The phase IIb studies SILEN-C1 and SILEN-C3 combined the protease inhibitor with standard of care pegylated interferon (PegIFN) and ribavirin (RBV) - which is only successful in about half of all cases - in previously untreated genotype 1 (GT1) HCV patients. > Continue reading this entire article:> http://www.inpharm.com/news/169774/boehringer-hails-hepatitis-c-candidate> Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 21, 2011 Report Share Posted November 21, 2011 Good luck , please keep us updated!!! hugs, jax To: "Hepatitis_C_Central " <Hepatitis_C_Central > Sent: Monday, November 21, 2011 9:45 AMSubject: Re: Re: Fw: New Drug Hi , I am going to start treatment in January, but they are putting me on the Vertex drug. I believe that starts right away and in 4 weeks if I am not clear, I am done and off all treatment. If I do clear, they told me to expect to be on treatment the rest of the year. I hope all goes well for you and treatment is not too hard on you! Steph To: Hepatitis_C_Central Sent: Sunday, November 20, 2011 9:45 AMSubject: Re: Re: Fw: New Drug I am in my 3rd week of interferon treatment. Next week I start that drug. Its for 12 weeks. I will keep you all posted on how its going. Last week my wbc dropped to 1.6 so they gave me a shot of nupr. I feel okay just a little ichy which I did not have last time. I have been working full days so far. Lets see how it goes. I have a good attitude. Subject: Re: Fw: New DrugTo: Hepatitis_C_Central Date: Saturday, November 19, 2011, 12:49 PM I wonder if the side effects would be worse. Penny > > > Boehringer's Hepatitis C Drug Candidate May Compete with the Newest Treatments > Treatment Time Gets Shorter > > November 14, 2011 > Printer-friendly version > Similar to the new Hepatitis C drug Telaprevir, Boehringer's protease inhibitor could reduce total treatment time to three months and improve the chances of success in the hardest-to-treat Hep C cases. > Boehringer hails hepatitis C candidate > Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients' treatment time and help in hard-to-treat cases. > The treatment of hepatitis C has moved forward recently, with Janssen's Incivo (telaprevir) and Merck and Roche's Victrelis (boceprevir) both recently launched in Europe. > Boehringer says its drug BI 201335 could cut the time a patient needed to take the drug to 12 weeks, matching the performance of Incivo. > The phase IIb studies SILEN-C1 and SILEN-C3 combined the protease inhibitor with standard of care pegylated interferon (PegIFN) and ribavirin (RBV) - which is only successful in about half of all cases - in previously untreated genotype 1 (GT1) HCV patients. > Continue reading this entire article: > http://www.inpharm.com/news/169774/boehringer-hails-hepatitis-c-candidate > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 21, 2011 Report Share Posted November 21, 2011 Hi , Good luck to you to. I know it was a tough choice. How are you????? Are you going to work through treatment? xx Subject: Re: Fw: New DrugTo: Hepatitis_C_Central Date: Saturday, November 19, 2011, 12:49 PM I wonder if the side effects would be worse. Penny > > > Boehringer's Hepatitis C Drug Candidate May Compete with the Newest Treatments > Treatment Time Gets Shorter > > November 14, 2011 > Printer-friendly version > Similar to the new Hepatitis C drug Telaprevir, Boehringer's protease inhibitor could reduce total treatment time to three months and improve the chances of success in the hardest-to-treat Hep C cases. > Boehringer hails hepatitis C candidate > Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients' treatment time and help in hard-to-treat cases. > The treatment of hepatitis C has moved forward recently, with Janssen's Incivo (telaprevir) and Merck and Roche's Victrelis (boceprevir) both recently launched in Europe. > Boehringer says its drug BI 201335 could cut the time a patient needed to take the drug to 12 weeks, matching the performance of Incivo. > The phase IIb studies SILEN-C1 and SILEN-C3 combined the protease inhibitor with standard of care pegylated interferon (PegIFN) and ribavirin (RBV) - which is only successful in about half of all cases - in previously untreated genotype 1 (GT1) HCV patients. > Continue reading this entire article: > http://www.inpharm.com/news/169774/boehringer-hails-hepatitis-c-candidate > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 21, 2011 Report Share Posted November 21, 2011 Hi , Good luck to you to. I know it was a tough choice. How are you????? Are you going to work through treatment? xx Subject: Re: Fw: New DrugTo: Hepatitis_C_Central Date: Saturday, November 19, 2011, 12:49 PM I wonder if the side effects would be worse. Penny > > > Boehringer's Hepatitis C Drug Candidate May Compete with the Newest Treatments > Treatment Time Gets Shorter > > November 14, 2011 > Printer-friendly version > Similar to the new Hepatitis C drug Telaprevir, Boehringer's protease inhibitor could reduce total treatment time to three months and improve the chances of success in the hardest-to-treat Hep C cases. > Boehringer hails hepatitis C candidate > Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients' treatment time and help in hard-to-treat cases. > The treatment of hepatitis C has moved forward recently, with Janssen's Incivo (telaprevir) and Merck and Roche's Victrelis (boceprevir) both recently launched in Europe. > Boehringer says its drug BI 201335 could cut the time a patient needed to take the drug to 12 weeks, matching the performance of Incivo. > The phase IIb studies SILEN-C1 and SILEN-C3 combined the protease inhibitor with standard of care pegylated interferon (PegIFN) and ribavirin (RBV) - which is only successful in about half of all cases - in previously untreated genotype 1 (GT1) HCV patients. > Continue reading this entire article: > http://www.inpharm.com/news/169774/boehringer-hails-hepatitis-c-candidate > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 21, 2011 Report Share Posted November 21, 2011 Hi , Good luck to you to. I know it was a tough choice. How are you????? Are you going to work through treatment? xx Subject: Re: Fw: New DrugTo: Hepatitis_C_Central Date: Saturday, November 19, 2011, 12:49 PM I wonder if the side effects would be worse. Penny > > > Boehringer's Hepatitis C Drug Candidate May Compete with the Newest Treatments > Treatment Time Gets Shorter > > November 14, 2011 > Printer-friendly version > Similar to the new Hepatitis C drug Telaprevir, Boehringer's protease inhibitor could reduce total treatment time to three months and improve the chances of success in the hardest-to-treat Hep C cases. > Boehringer hails hepatitis C candidate > Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients' treatment time and help in hard-to-treat cases. > The treatment of hepatitis C has moved forward recently, with Janssen's Incivo (telaprevir) and Merck and Roche's Victrelis (boceprevir) both recently launched in Europe. > Boehringer says its drug BI 201335 could cut the time a patient needed to take the drug to 12 weeks, matching the performance of Incivo. > The phase IIb studies SILEN-C1 and SILEN-C3 combined the protease inhibitor with standard of care pegylated interferon (PegIFN) and ribavirin (RBV) - which is only successful in about half of all cases - in previously untreated genotype 1 (GT1) HCV patients. > Continue reading this entire article: > http://www.inpharm.com/news/169774/boehringer-hails-hepatitis-c-candidate > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 21, 2011 Report Share Posted November 21, 2011 I hope to. I do have almost 200 hours of vacation and 80 hours of sick leave at this time. I am hoping that that will cover me. My boss is very good about everything. The thing is that I will know in 4 weeks if it is working. How are you feeling? Are you going through a doc near where you live? Dr Tram did say that there are "promising :new drugs in the pipeline not using the other 2 drugs, but they are several years away and may fizzle.AND I will be too old to go through treatment. May chance is now! My very best to you!!! To: Hepatitis_C_Central Sent: Monday, November 21, 2011 10:48 AMSubject: Re: Re: Fw: New Drug Hi , Good luck to you to. I know it was a tough choice. How are you????? Are you going to work through treatment? xx Subject: Re: Fw: New DrugTo: Hepatitis_C_Central Date: Saturday, November 19, 2011, 12:49 PM I wonder if the side effects would be worse. Penny > > > Boehringer's Hepatitis C Drug Candidate May Compete with the Newest Treatments > Treatment Time Gets Shorter > > November 14, 2011 > Printer-friendly version > Similar to the new Hepatitis C drug Telaprevir, Boehringer's protease inhibitor could reduce total treatment time to three months and improve the chances of success in the hardest-to-treat Hep C cases. > Boehringer hails hepatitis C candidate > Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients' treatment time and help in hard-to-treat cases. > The treatment of hepatitis C has moved forward recently, with Janssen's Incivo (telaprevir) and Merck and Roche's Victrelis (boceprevir) both recently launched in Europe. > Boehringer says its drug BI 201335 could cut the time a patient needed to take the drug to 12 weeks, matching the performance of Incivo. > The phase IIb studies SILEN-C1 and SILEN-C3 combined the protease inhibitor with standard of care pegylated interferon (PegIFN) and ribavirin (RBV) - which is only successful in about half of all cases - in previously untreated genotype 1 (GT1) HCV patients. > Continue reading this entire article: > http://www.inpharm.com/news/169774/boehringer-hails-hepatitis-c-candidate > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 21, 2011 Report Share Posted November 21, 2011 Will do, thanks! When I start, I will let you know. To: "Hepatitis_C_Central " <Hepatitis_C_Central > Sent: Monday, November 21, 2011 10:47 AMSubject: Re: Re: Fw: New Drug Good luck , please keep us updated!!! hugs, jax To: "Hepatitis_C_Central " <Hepatitis_C_Central > Sent: Monday, November 21, 2011 9:45 AMSubject: Re: Re: Fw: New Drug Hi , I am going to start treatment in January, but they are putting me on the Vertex drug. I believe that starts right away and in 4 weeks if I am not clear, I am done and off all treatment. If I do clear, they told me to expect to be on treatment the rest of the year. I hope all goes well for you and treatment is not too hard on you! Steph To: Hepatitis_C_Central Sent: Sunday, November 20, 2011 9:45 AMSubject: Re: Re: Fw: New Drug I am in my 3rd week of interferon treatment. Next week I start that drug. Its for 12 weeks. I will keep you all posted on how its going. Last week my wbc dropped to 1.6 so they gave me a shot of nupr. I feel okay just a little ichy which I did not have last time. I have been working full days so far. Lets see how it goes. I have a good attitude. Subject: Re: Fw: New DrugTo: Hepatitis_C_Central Date: Saturday, November 19, 2011, 12:49 PM I wonder if the side effects would be worse. Penny > > > Boehringer's Hepatitis C Drug Candidate May Compete with the Newest Treatments > Treatment Time Gets Shorter > > November 14, 2011 > Printer-friendly version > Similar to the new Hepatitis C drug Telaprevir, Boehringer's protease inhibitor could reduce total treatment time to three months and improve the chances of success in the hardest-to-treat Hep C cases. > Boehringer hails hepatitis C candidate > Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients' treatment time and help in hard-to-treat cases. > The treatment of hepatitis C has moved forward recently, with Janssen's Incivo (telaprevir) and Merck and Roche's Victrelis (boceprevir) both recently launched in Europe. > Boehringer says its drug BI 201335 could cut the time a patient needed to take the drug to 12 weeks, matching the performance of Incivo. > The phase IIb studies SILEN-C1 and SILEN-C3 combined the protease inhibitor with standard of care pegylated interferon (PegIFN) and ribavirin (RBV) - which is only successful in about half of all cases - in previously untreated genotype 1 (GT1) HCV patients. > Continue reading this entire article: > http://www.inpharm.com/news/169774/boehringer-hails-hepatitis-c-candidate > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 21, 2011 Report Share Posted November 21, 2011 Will do, thanks! When I start, I will let you know. To: "Hepatitis_C_Central " <Hepatitis_C_Central > Sent: Monday, November 21, 2011 10:47 AMSubject: Re: Re: Fw: New Drug Good luck , please keep us updated!!! hugs, jax To: "Hepatitis_C_Central " <Hepatitis_C_Central > Sent: Monday, November 21, 2011 9:45 AMSubject: Re: Re: Fw: New Drug Hi , I am going to start treatment in January, but they are putting me on the Vertex drug. I believe that starts right away and in 4 weeks if I am not clear, I am done and off all treatment. If I do clear, they told me to expect to be on treatment the rest of the year. I hope all goes well for you and treatment is not too hard on you! Steph To: Hepatitis_C_Central Sent: Sunday, November 20, 2011 9:45 AMSubject: Re: Re: Fw: New Drug I am in my 3rd week of interferon treatment. Next week I start that drug. Its for 12 weeks. I will keep you all posted on how its going. Last week my wbc dropped to 1.6 so they gave me a shot of nupr. I feel okay just a little ichy which I did not have last time. I have been working full days so far. Lets see how it goes. I have a good attitude. Subject: Re: Fw: New DrugTo: Hepatitis_C_Central Date: Saturday, November 19, 2011, 12:49 PM I wonder if the side effects would be worse. Penny > > > Boehringer's Hepatitis C Drug Candidate May Compete with the Newest Treatments > Treatment Time Gets Shorter > > November 14, 2011 > Printer-friendly version > Similar to the new Hepatitis C drug Telaprevir, Boehringer's protease inhibitor could reduce total treatment time to three months and improve the chances of success in the hardest-to-treat Hep C cases. > Boehringer hails hepatitis C candidate > Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients' treatment time and help in hard-to-treat cases. > The treatment of hepatitis C has moved forward recently, with Janssen's Incivo (telaprevir) and Merck and Roche's Victrelis (boceprevir) both recently launched in Europe. > Boehringer says its drug BI 201335 could cut the time a patient needed to take the drug to 12 weeks, matching the performance of Incivo. > The phase IIb studies SILEN-C1 and SILEN-C3 combined the protease inhibitor with standard of care pegylated interferon (PegIFN) and ribavirin (RBV) - which is only successful in about half of all cases - in previously untreated genotype 1 (GT1) HCV patients. > Continue reading this entire article: > http://www.inpharm.com/news/169774/boehringer-hails-hepatitis-c-candidate > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 22, 2011 Report Share Posted November 22, 2011 You know I feel good. My symptoms are just the opposite of last time. I had fatigue and nausea and this time I have itching and mood swings. Go figure. I am on a 16 week deal. 4 weeks of interferon and riba and then another 12 weeks of all 3 drugs. Of course that's if I am clean at the 4 weeks which is next week. I had a low viral load to start 200,000. It stayed low since last treatment. I hope to just hammer through. Keep me posted. Oh and yes I see my local doctor here in OC. xx Subject: Re: Fw: New DrugTo: Hepatitis_C_Central Date: Saturday, November 19, 2011, 12:49 PM I wonder if the side effects would be worse. Penny > > > Boehringer's Hepatitis C Drug Candidate May Compete with the Newest Treatments > Treatment Time Gets Shorter > > November 14, 2011 > Printer-friendly version > Similar to the new Hepatitis C drug Telaprevir, Boehringer's protease inhibitor could reduce total treatment time to three months and improve the chances of success in the hardest-to-treat Hep C cases. > Boehringer hails hepatitis C candidate > Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients' treatment time and help in hard-to-treat cases. > The treatment of hepatitis C has moved forward recently, with Janssen's Incivo (telaprevir) and Merck and Roche's Victrelis (boceprevir) both recently launched in Europe. > Boehringer says its drug BI 201335 could cut the time a patient needed to take the drug to 12 weeks, matching the performance of Incivo. > The phase IIb studies SILEN-C1 and SILEN-C3 combined the protease inhibitor with standard of care pegylated interferon (PegIFN) and ribavirin (RBV) - which is only successful in about half of all cases - in previously untreated genotype 1 (GT1) HCV patients. > Continue reading this entire article: > http://www.inpharm.com/news/169774/boehringer-hails-hepatitis-c-candidate > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 22, 2011 Report Share Posted November 22, 2011 You know I feel good. My symptoms are just the opposite of last time. I had fatigue and nausea and this time I have itching and mood swings. Go figure. I am on a 16 week deal. 4 weeks of interferon and riba and then another 12 weeks of all 3 drugs. Of course that's if I am clean at the 4 weeks which is next week. I had a low viral load to start 200,000. It stayed low since last treatment. I hope to just hammer through. Keep me posted. Oh and yes I see my local doctor here in OC. xx Subject: Re: Fw: New DrugTo: Hepatitis_C_Central Date: Saturday, November 19, 2011, 12:49 PM I wonder if the side effects would be worse. Penny > > > Boehringer's Hepatitis C Drug Candidate May Compete with the Newest Treatments > Treatment Time Gets Shorter > > November 14, 2011 > Printer-friendly version > Similar to the new Hepatitis C drug Telaprevir, Boehringer's protease inhibitor could reduce total treatment time to three months and improve the chances of success in the hardest-to-treat Hep C cases. > Boehringer hails hepatitis C candidate > Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients' treatment time and help in hard-to-treat cases. > The treatment of hepatitis C has moved forward recently, with Janssen's Incivo (telaprevir) and Merck and Roche's Victrelis (boceprevir) both recently launched in Europe. > Boehringer says its drug BI 201335 could cut the time a patient needed to take the drug to 12 weeks, matching the performance of Incivo. > The phase IIb studies SILEN-C1 and SILEN-C3 combined the protease inhibitor with standard of care pegylated interferon (PegIFN) and ribavirin (RBV) - which is only successful in about half of all cases - in previously untreated genotype 1 (GT1) HCV patients. > Continue reading this entire article: > http://www.inpharm.com/news/169774/boehringer-hails-hepatitis-c-candidate > Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.